These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 2082906)
21. Editorial: Is control of hyperlipidaemia important in renal diseases? Med J Aust; 1974 Jul; 2(4):115-8. PubMed ID: 4608833 [No Abstract] [Full Text] [Related]
22. Achieving maximal renal protection in nondiabetic chronic renal disease. Taal MW; Brenner BM Am J Kidney Dis; 2001 Dec; 38(6):1365-71. PubMed ID: 11728976 [TBL] [Abstract][Full Text] [Related]
23. Diagnosis and classification of dyslipidemia in renal disease. Attman PO; Samuelsson O; Alaupovic P Blood Purif; 1996; 14(1):49-57. PubMed ID: 8718566 [TBL] [Abstract][Full Text] [Related]
25. Plasma fibronectin in normolipidaemic and hyperlipidaemic uraemic patients treated with haemodialysis. De Giorgio LA; Maffucci G; Toscano G; Gironi A; Vignoli S; Seghieri G Clin Chim Acta; 1987 Oct; 168(3):281-6. PubMed ID: 3677426 [TBL] [Abstract][Full Text] [Related]
26. Lipid abnormalities in maintenance dialysis patients and renal transplant recipients. Ponticelli C; Barbi G; Cantaluppi A; Donati C; Annoni G; Brancaccio D Kidney Int Suppl; 1978 Jun; (8):S72-8. PubMed ID: 357818 [No Abstract] [Full Text] [Related]
27. [Ways to inhibit development of chronic renal failure]. Tareeva IE; Kutyrina IM; Nikolaev AIu; Lifshits NL; Shvetsov MIu Ter Arkh; 2000; 72(6):9-14. PubMed ID: 10900641 [No Abstract] [Full Text] [Related]
28. Statin therapy in patients with chronic kidney disease: to use or not to use. Steinmetz OM; Panzer U; Stahl RA; Wenzel UO Eur J Clin Invest; 2006 Aug; 36(8):519-27. PubMed ID: 16893373 [TBL] [Abstract][Full Text] [Related]
29. [Hyperlipidemia in renal diseases]. Yukawa S; Maeda T; Mune M; Yamada Y; Ohtani H; Matoba K; Bando K; Mimura K; Nomoto H Nihon Rinsho; 1990 Nov; 48(11):2578-84. PubMed ID: 2270024 [No Abstract] [Full Text] [Related]
30. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease. Vaziri ND J Ren Nutr; 2010 Sep; 20(5 Suppl):S35-43. PubMed ID: 20797569 [TBL] [Abstract][Full Text] [Related]
31. Dyslipidemia and renal disease: pathogenesis and clinical consequences. Wanner C; Quaschning T Curr Opin Nephrol Hypertens; 2001 Mar; 10(2):195-201. PubMed ID: 11224694 [TBL] [Abstract][Full Text] [Related]
32. [Lipoprotein disorders in chronic kidney failure, nephrotic syndrome and dialysis]. Kes P; Reiner Z; Brunetta B Lijec Vjesn; 2002; 124(11-12):372-7. PubMed ID: 12679979 [TBL] [Abstract][Full Text] [Related]
33. Dyslipidemia and its management after renal transplantation. Andany MA; Kasiske BL J Nephrol; 2001; 14 Suppl 4():S81-8. PubMed ID: 11798152 [TBL] [Abstract][Full Text] [Related]
34. Cholesterol as a predictor of progression in nondiabetic chronic renal disease. Greco BA; Breyer JA Contrib Nephrol; 1997; 120():48-61. PubMed ID: 9257047 [TBL] [Abstract][Full Text] [Related]
35. Lipoprotein metabolism and lipid management in chronic kidney disease. Kwan BC; Kronenberg F; Beddhu S; Cheung AK J Am Soc Nephrol; 2007 Apr; 18(4):1246-61. PubMed ID: 17360943 [No Abstract] [Full Text] [Related]
36. Should hyperlipidaemia in dialysis patients be treated? Wheeler DC Nephrol Dial Transplant; 1997 Jan; 12(1):19-21. PubMed ID: 9027766 [No Abstract] [Full Text] [Related]